MiMedx Group Stock Soars 16.81% on Analyst Upgrade

MiMedx Group's stock surged 16.81% in pre-market trading on April 14, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Northland Capital analysts have highlighted MiMedx as a significantly undervalued stock, suggesting that its current share price does not fully reflect the company's improving business fundamentals and potential future gains. They describe the stock as "oversold," positioning it as a promising buying opportunity for investors. The firm has reiterated its "Outperform" rating on MiMedx, affirming a target price of $12. This assessment is based on the anticipation of positive impacts from the implementation of pending Local Coverage Determinations (LCDs), which could enhance the company's valuation. The analysts believe the market has not yet recognized these potential catalysts, making MiMedx an attractive option for investors seeking growth.

Based on the one-year price targets offered by analysts, the average target price for MiMedx Group Inc is $13.75 with a high estimate of $16.00 and a low estimate of $12.00. The average target implies an upside of 102.21% from the current price. The consensus recommendation from brokerage firms indicates an "Outperform" status for MiMedx Group Inc, with a rating scale ranging from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.